Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases-Reference-Cited by-同舟云学术

Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases

Published:2020-01-22 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Guo Yong-Zhi,Jiang Ying-Nan,Li Yi-Fang,Kurihara Hiroshi,Dai Yi,He Rong-Rong

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference80 articles.

1. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy;Al-Damry;Biomed. Pharmacother.,2018

2. Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction;Asensio-Lopez;Transl. Res.,2018

3. Interactions between traditional Chinese medicines and Western therapeutics;Chan;Curr. Opin. Drug Discovery Devel.,2010

4. Acacetin protects against cardiac remodeling after myocardial infarction by mediating MAPK and PI3K/Akt signal pathway;Chang;J. Pharmacol. Sci.,2017

5. Buyanghuanwu Decoction alleviated pressure overload induced cardiac remodeling by suppressing Tgf-β/Smads and MAPKs signaling activated fibrosis;Chen;Biomed. Pharmacother.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osteogenic Differentiation of Human Umbilical Cord Blood Mesenchymal Stem Cells Induced by Liu’s Zhenggudan No. 2 Formula;Evidence-Based Complementary and Alternative Medicine;2022-09-06

2. Integrative medicine perspectives;Mechanisms of Action in Disease and Recovery in Integrative Cardiovascular Chinese Medicine;2021